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ortic Stenosis:
Fatal Disease With But
Single Cure*
lase A. Carabello, MD, FACC
ouston, Texas
ortic stenosis (AS) is narrowing of the aortic valve creating
n obstruction to outflow of blood into the systemic
irculation. As AS worsens, the force the left ventricle must
enerate to overcome the obstruction increases progres-
ively. Although inotropic reserve and the development of
eft ventricular hypertrophy serve initially to compensate for
his increase in demand, these double-edged swords lead
lso to pathologic consequences, the onset of symptoms,
orbidity, and mortality. Indeed there are few diseases in
ardiology more lethal than severe symptomatic AS. Within
years of the onset of angina, syncope, or the symptoms of
eart failure, 75% of symptomatic patients are dead unless
he outflow obstruction is relieved by aortic valve replace-
ent (AVR) (1). Thus before AVR there is a striking
ortality risk of 2% a month. Almost all medical decisions
See page 122
egarding therapy are driven by weighing risks versus
enefits of that therapy. Accordingly, there are few more
triking contrasts in cardiology than between this huge risk
f dying for the symptomatic AS patient versus the benefits
f AVR (Fig. 1) (2). Still many patients with severe AS do
ot undergo AVR. Although advanced age by itself should
ever be considered a contraindication to AVR, risk of AVR
s increased in older patients especially when comorbidities
re present (3–5). Thus there are many patients whose
hysicians are reluctant to recommend AVR or who are
eluctant to undergo AVR despite the recommendation to
o so.
Enter again the risk-benefit ratio. Standard AVR is
erformed during general anesthesia with the aid of cardio-
ulmonary bypass. Although risk might be as low as 1% in
ompensated patients operated at high-volume centers (6),
Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.m
From the Department of Medicine, Baylor College of Medicine, and Veterans
ffairs Medical Center, Houston, Texas.sual risk is approximately 4%, growing to 10% to 30% in
ompromised patients (7). Risk is increased by the co-
resence of coronary artery disease, severe myocardial dys-
unction, far-advanced age, and the presence of other
ystemic illnesses. But if the risk of AVR could be reduced
urther, AVR would become progressively more palatable.
Obviously the prospect of AVR done transapically or
ercutaneously as presented by Webb (8) in this issue of the
ACC: Cardiovascular Interventions opens new doors to
VR not conceived of by most of us just 5 years ago. With
he transapical approach, a stented valve is inserted through
small thoracotomy into the apex of a beating left ventricle
nder anesthesia but without extracorporeal circulation.
his approach avoids percutaneous access problems present
n many older patients but obviously still requires surgery. In
ontrast, the percutaneous approach can be performed in
wake patients without surgery. Both methods have steep
earning curves, and both methods are still experimental in
he U.S. Complications of the percutaneous approach are
rimarily related to the difficulties at the point of vascular
ccess and of maneuvering the large bore delievery system
round tortous atherosclerotic vessels. These include vessel
aceration and dislodgement of atherosclerotic debris and
ubsequent embolization. Both methods often result in mild
aravalvular leaks that are usually hemodynamically insig-
ificant. To the investigators’ credit, all ethical issues have
een avoided by proceeding only in very ill patients who
ere considered inoperable from standard approaches. In
iew of these substantial hurdles, the initial success reported
n both sides of the Atlantic, with 2 different valve designs
s striking and very encouraging (9,10).
Certainly we were here once before in the mid-1980s.
hen, balloon valvotomy initially was greeted with much
nthusiasm as a percutaneous solution to AS, only to rapidly
all out of favor when results only modestly reduced outflow
bstruction and then usually only for a short period of time,
ventually having little impact on the extreme mortality rate
f untreated severe symptomatic AS (11).
But this is different. Now the aortic valve is being
eplaced, and if all else is equal, a replacement is a replace-
ent is a replacement. A percutaneous or transapically
erformed AVR will have at least some the benefits and
isks of surgically implanted valves. The benefit of relief of
utflow obstruction seems very similar to many currently
vailable surgically placed valves. The major complication of
uch valves, structural deterioration, is obviously unknown
or percutaneously implanted valves, and only the passage of
ime will address that issue. Although one might predict
hat because the materials used are similar to those of other
iologic valves, they might last as long. However, predica-
ions of valve durability have been notoriously flawed in the
ast. It is fairly predictable that access-related problems will
e reduced by engineering technology that has a way of
iniaturizing things and overcoming existing hurdles and
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128hat durability (if it turned out to be a problem) will improve
ith subsequent valve generations.
So, what would we do if we had a percutaneously installed
VR that was durable and could be placed safely? Wouldn’t
t revolutionize the therapy for AS? First, let us admit that
his is not a certainty. In the extensive data available for
ercutaneous coronary interventions, there is little proof
hat outcome, at least with respect to overall mortality, is
ny less than with bypass surgery (12). To be sure, percu-
aneous approaches are less painful and result in shorter
ospital stays, but overall the results of the 2 methods are
argely similar. In coronary revascularization, however, the
omparison is between 2 entirely different techniques that
rovide improved myocardial perfusion. In the case of AVR,
hether placed transaortically, apically, or percutaneously,
he end product is still an AVR. And it already seems that
he technique has opened new doors. Unlike the early uses
f percutaneous coronary revascularization where virtually
ll the patients were surgical candidates and could be
perated if the procedure ran amiss, the patients treated
ith percutaneous and apical AVR presumably would have
een otherwise left to the dire fate of unoperated patients
ith AS.
Who will install these valves, and where? There is clearly
ngst among heart surgeons that AVR, once entirely in their
omain, will become the bailiwick of the interventional
Figure 1. Survival in Aortic Stenosis
Demonstrates the stark difference in survival of patients with symptomatic
aortic stenosis between those who were and those who were not treated
with aortic valve replacement (AVR). Reprinted, with permission, from
Schwarz et al. (2).ardiologist in the same way that coronary revascularizationas. I, for one, hope not. Each discipline, cardiology and
ardiac surgery, possesses special knowledge and skills not
eld by the other. It is likely that the best outcomes for this
ew procedure will occur when both disciplines bring their
kill sets to bear on the same patient in a hybrid operating
oom or catheterization laboratory. There, surgeons will
ring forth their knowledge of prosthetic valves and anat-
my, with the cardiologist providing unique catheter skills
o the mix. Vascular surgeons, anesthesiologists, and imag-
ng specialists can add further skills, enhancing outcome.
Severe symptomatic AS is a universally fatal disease that
mparts misery by way of angina syncope and heart failure
efore death. Despite dramatic improvements in surgery,
any patients are not availed of it for one reason or another.
opefully transapical and percutaneous approaches added
o traditional surgery will make life-saving AVR available to
early anyone who needs it. Given the relative safety of
hese devices in the very ill patients treated thus far, I hope
he devices and their successors will become widely available
n the very near future.
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